Generic drug maker Barr Pharmaceuticals Inc. (BRL) Monday said its subsidiary Barr Laboratories has initiated a challenge of Ireland-based Azur Pharma's patent suit with regard to Barr's Abbreviated New Drug Application for the 25 mg and 100mg doses of FazaClo, an orally disintegrating tablet formulation of clozapine.
Montvale, New Jersey-based Barr dismissed Azur's patent claims and asserted that it was the first to file an Abbreviated New Drug Application for FazaClo, which had annual sales of about $34 million in the U.S.
Last week, Azur, together with Cima Labs, filed a patent lawsuit in the Delaware district court seeking a ban on the commercialization of FazaClo.
FazaClo is approved for the treatment of advanced-stage schizophrenic patients who fail to respond to standard treatments. The drug is also indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorders.
BRL is currently trading at $67.03, down $0.32 or 0.48%, on a volume of about 204 thousand shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.